An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research

Overview

Journal Curr Drug Abuse Rev

Publisher Bentham Science Publishers

Specialty Psychiatry

Date 2015 Mar 10

PMID 25751583

Citations 14

Authors

Lisa R Norman

Michael Basso

Affiliations

Soon will be listed here.

Abstract

Neuropyschological dysfunction, ranging from mild cerebral indicators to dementia has been a consistent part of the medical picture of HIV/AIDS. However, advances in medical supervision, particularly as a result of antiretroviral (ARV) treatment, have resulted in some mitigation of the neuropsychological effects of HIV and necessitate re-evaluation of the pattern and nature of HIV-related cognitive or mental deficits. The associated enhancements in morbidity and mortality that have occurred as a result of ARV medication have led to a need for interventions and programs that maintain behaviors that are healthy and stop the resurgence of the risk of HIV transmission. Risk factors such as mental illness and substance use that may have contributed to the initial infection with HIV still need consideration. These risk factors may also increase neuropsychological dysfunction and impact observance of prevention for treatment and recommendations. Explicitly, a better comprehension of the role of substance use on the progression of HIV-related mental decline can enlighten management and evaluation of persons living with HIV with concurrent disorders of substance use. This review provides a summary of the neurophyschology of substance use and HIV and the existing research that has looked at the effects of both substance use and HIV disease on neurophyscological function and suggestions for future research and treatment.

Citing Articles

HIV chronicity as a predictor of hippocampal memory deficits in daily cannabis users living with HIV.

Woodcock E, Greenwald M, Chen I, Feng D, Cohn J, Lundahl L Drug Alcohol Depend Rep. 2023; 9:100189.

PMID: 37736522 PMC: 10509297. DOI: 10.1016/j.dadr.2023.100189.

Longitudinal changes in neurocognitive performance related to drug use intensity in a sample of persons with and without HIV who use illicit stimulants.

Towe S, Tang R, Gibson M, Zhang A, Meade C Drug Alcohol Depend. 2023; 251:110923.

PMID: 37598454 PMC: 10538396. DOI: 10.1016/j.drugalcdep.2023.110923.

The Combined Effects of Cannabis, Methamphetamine, and HIV on Neurocognition.

Rogers J, Iudicello J, Marcondes M, Morgan E, Cherner M, Ellis R Viruses. 2023; 15(3).

PMID: 36992383 PMC: 10058939. DOI: 10.3390/v15030674.

Impaired verbal memory in individuals living with HIV and cocaine dependence.

Nigro S, Wu M, Juliano A, Napier T, Landay A, French A J Clin Exp Neuropsychol. 2022; 44(2):134-145.

PMID: 35786160 PMC: 9388195. DOI: 10.1080/13803395.2022.2086219.

Central Nervous System Effects of COVID-19 in People with HIV Infection.

Peluso M, Hellmuth J, Chow F Curr HIV/AIDS Rep. 2021; 18(6):538-548.

PMID: 34843065 PMC: 8628487. DOI: 10.1007/s11904-021-00582-x.

References

Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher M . Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol. 2011; 17(4):291-302. PMC: 3757547. DOI: 10.1007/s13365-011-0037-2. View

Monnig M, Tonigan J, Yeo R, Thoma R, McCrady B . White matter volume in alcohol use disorders: a meta-analysis. Addict Biol. 2012; 18(3):581-92. PMC: 3390447. DOI: 10.1111/j.1369-1600.2012.00441.x. View

Flora G, Lee Y, Nath A, Hennig B, Maragos W, Toborek M . Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol. 2002; 179(1):60-70. DOI: 10.1006/exnr.2002.8048. View

Meade C, Conn N, Skalski L, Safren S . Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2010; 34(2):128-38. PMC: 3049963. DOI: 10.1007/s10865-010-9293-5. View

Cole M, Margolick J, Cox C, Li X, Selnes O, Martin E . Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007; 69(24):2213-20. DOI: 10.1212/01.WNL.0000277520.94788.82. View

Meade C, Lowen S, MacLean R, Key M, Lukas S . fMRI brain activation during a delay discounting task in HIV-positive adults with and without cocaine dependence. Psychiatry Res. 2011; 192(3):167-75. PMC: 3097316. DOI: 10.1016/j.pscychresns.2010.12.011. View

Park S, Kahnt T, Beck A, Cohen M, Dolan R, Wrase J . Prefrontal cortex fails to learn from reward prediction errors in alcohol dependence. J Neurosci. 2010; 30(22):7749-53. PMC: 3047386. DOI: 10.1523/JNEUROSCI.5587-09.2010. View

Lovejoy T, Suhr J . The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009; 32(5):389-405. DOI: 10.1007/s10865-009-9212-9. View

Kreek M, Bart G, Lilly C, LaForge K, Nielsen D . Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005; 57(1):1-26. DOI: 10.1124/pr.57.1.1. View

10.

Jovanovski D, Erb S, Zakzanis K . Neurocognitive deficits in cocaine users: a quantitative review of the evidence. J Clin Exp Neuropsychol. 2005; 27(2):189-204. DOI: 10.1080/13803390490515694. View

11.

Shoptaw S, Stall R, Bordon J, Kao U, Cox C, Li X . Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study. Int J STD AIDS. 2012; 23(8):576-80. PMC: 3576843. DOI: 10.1258/ijsa.2012.011322. View

12.

Iyo M, Namba H, Yanagisawa M, Hirai S, Yui N, Fukui S . Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21(5):789-96. DOI: 10.1016/s0278-5846(97)00079-1. View

13.

Woods S, Moore D, Weber E, Grant I . Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009; 19(2):152-68. PMC: 2690857. DOI: 10.1007/s11065-009-9102-5. View

14.

Schottenbauer M, Momenan R, Kerick M, Hommer D . Relationships among aging, IQ, and intracranial volume in alcoholics and control subjects. Neuropsychology. 2007; 21(3):337-45. DOI: 10.1037/0894-4105.21.3.337. View

15.

Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S . Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(11):9307-12. PMC: 110352. DOI: 10.1128/JVI.72.11.9307-9312.1998. View

16.

Kopnisky K, Bao J, Lin Y . Neurobiology of HIV, psychiatric and substance abuse comorbidity research: workshop report. Brain Behav Immun. 2007; 21(4):428-41. DOI: 10.1016/j.bbi.2007.01.011. View

17.

Copenhaver M, Avants S, Warburton L, Margolin A . Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoactive Drugs. 2003; 35(2):209-18. DOI: 10.1080/02791072.2003.10400002. View

18.

Gonzalez-Scarano F, Martin-Garcia J . The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5(1):69-81. DOI: 10.1038/nri1527. View

19.

Bartok J, Martin E, Pitrak D, Novak R, Pursell K, Mullane K . Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997; 3(5):451-6. View

20.

Schulte T, Mueller-Oehring E, Rosenbloom M, Pfefferbaum A, Sullivan E . Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: evidence from a Stroop Match-to-Sample task. Biol Psychiatry. 2004; 57(1):67-75. DOI: 10.1016/j.biopsych.2004.09.025. View